Vir Biotechnology upgraded by Goldman with a new price target

2/21/23 6:26:37 AM ET

Biotechnology: Biological Products (No Diagnostic Substances)

Health Care

Goldman upgraded Vir Biotechnology from Neutral to Buy and set a new price target of $53.00 from $41.00 previously

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$VIR

Date	Price Target	Rating	Analyst
1/29/2024	$23.00 → $9.00	Overweight → Neutral	JP Morgan
9/8/2023	$23.00 → $14.00	Buy → Neutral	BofA Securities
3/6/2023	$35.00 → $34.00	Neutral → Overweight	JP Morgan
2/21/2023	$41.00 → $53.00	Neutral → Buy	Goldman
1/27/2023	$18.00 → $30.00	Underweight → Equal-Weight	Morgan Stanley
9/14/2022	$40.00	Outperform	SVB Leerink
9/9/2022	$15.00	Underweight	Morgan Stanley
3/3/2022	$36.00 → $28.00	Underperform → Neutral	Baird